Spironolactone for Pulmonary Arterial Hypertension

Launched by NATIONAL INSTITUTES OF HEALTH CLINICAL CENTER (CC) · Oct 20, 2012

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called spironolactone on people with pulmonary arterial hypertension (PAH), a condition that causes high blood pressure in the lungs. PAH can be serious, and even with current treatments, it can be life-threatening. The researchers want to find out if spironolactone can improve lung blood vessel function and reduce inflammation in these patients. To participate, individuals must be at least 18 years old and have been stable on their current PAH treatment for at least four weeks.

Participants in the trial will take either spironolactone or a placebo (a non-active treatment) for 24 weeks. They will undergo regular check-ups that include blood tests, heart and lung function tests, and a simple walking test to see how far they can walk in six minutes. This study aims to determine if spironolactone can help improve the health and quality of life for those living with PAH. It's important to note that certain individuals, such as those with severe heart issues or specific medical conditions, may not be eligible to join.

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• 1. WHO Group 1 PH patients on either no medical therapy or stable medical therapy for at least the past 4 weeks (defined as no new PAH-specific therapy, no change in the dose of current PAH-specific therapy and no change in NYHA/WHO functional classification within the past 4 weeks) are eligible. The following parameters on RHC are required to meet the hemodynamic definition of PAH:
• • <!-- -->
• • 1. mean pulmonary artery pressure of \> 25 mmHg at rest,
• • 2. pulmonary capillary wedge pressure of less than or equal to 15 mmHg (or a left ventricular end-diastolic pressure of less than or equal to 12 mmHg) and
• • 3. pulmonary vascular resistance of \> 3 Wood units (240 dyn.s.cm\^-5).
• • If clinically indicated at the time of enrollment, then a RHC will be performed at the NIH Clinical Center upon study entry under a procedural consent.
• • 2) Females who are able to become pregnant (i.e., are not postmenopausal, have not undergone surgical sterilization, and are sexually active with men) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to and for the duration of study participation.
• EXCLUSION CRITERIA:
• 1. Patients with WHO Group 1 PH and evidence of right heart failure as defined by:
• • 1. NYHA/WHO class IV symptoms and
• • 2. Echocardiographic evidence of severe RV dysfunction and
• • 3. Clinical evidence of right heart failure which may include, but is not limited to elevated jugular venous pressure, ascites, and lower extremity edema
• • 2. Patients with WHO Group 1 pulmonary hypertension and a prior diagnosis of cirrhosis with portal hypertension as evidenced by a history of ascites, hepatic encephalopathy and/or varices prior to enrollment
• • 3. Patients with WHO Group 1 pulmonary hypertension and evidence of active infection, (HIV patients with two consecutive viral loads of \< 500 on their most recent determinations within the past 12 months will be considered to have inactive infection)
• • 4. Patients with WHO Group 1 pulmonary hypertension who have taken spironolactone or eplerenone within the last 30 days
• • 5. Known or suspected allergy to spironolactone
• • 6. Pregnant or breastfeeding women (all women of childbearing potential will be required to have a screening urine or blood pregnancy test)
• • 7. Age \<18 years
• • 8. Inability to provide informed written consent for participation in the study
• • 9. Chronic kidney disease (an estimated glomerular filtration rate of \< 35 mL/min/1.73m\^2 of body surface area)
• • 10. Serum potassium at the time of enrollment of \> 5 mEq/L
• • 11. Concurrent use of an ACE inhibitor and angiotensin II receptor blocker
• • OR
• • Patients currently taking the maximum recommended dose of an ACE inhibitor or an angiotensin II receptor blocker \[For patients taking one of these medicines (ACE-Inhibitors or ARBs), the investigators agree to do due diligence by consulting a clinical center pharmacist and/or a standard pharmacy reference (i.e. Micromedex) to certify whether or not the patient is on a maximum dose of the drug.\]
• • 12. Women currently taking drospirenone-containing oral contraceptives
• • The estimated glomerular filtration rate (eGFR) will be calculated using the IDMS-traceable Modification of Diet in Renal Disease (MDRD) equation and corrected for body surface area.
• • eGFR = 175 x (serum creatinine in mg/dL)\^-1.154 x (age in years)\^-0.203 x \[1.212 if African-American\] x \[0.742 if female\]
• • Exclusion Criteria for MRI
• These contraindications include but are not limited to the following devices or conditions:
• • 1. Implanted cardiac pacemaker or defibrillator
• • 2. Cochlear Implants
• • 3. Ocular foreign body (e.g. metal shavings)
• • 4. Embedded shrapnel fragments
• • 5. Central nervous system aneurysm clips
• • 6. Implanted neural stimulator
• • 7. Any implanted device that is incompatible with MRI
• • 8. Unsatisfactory performance status as judged by the referring physician such that the subject could not tolerate an MRI scan. Examples of medical conditions that would not be accepted would include unstable angina and severe dyspnea at rest
• • 9. Subjects requiring monitored sedation for MRI studies
• • 10. Subjects with a condition precluding entry into the scanner (e.g. morbid obesity, claustrophobia, etc.)
• • 11. Subjects with severe back-pain or motion disorders who will be unable to tolerate supine positioning within the MRI scanner and hold still for the duration of the examination.
• EXCLUSION CRITERIA FOR GADOLINIUM BASED MRI STUDIES ONLY:
• • 1. History of severe allergic reaction to gadolinium contrast agents despite pre- medication with diphenhydramine and prednisone
• • 2. Chronic kidney disease (an estimated glomerular filtration rate of \< 60 mL/min/1.73m\^2 of body surface area)